Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-05-2005 | Concise Article

Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001

Authors: D. Martin, F. Persat, M.-A. Piens, S. Picot

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2005

Abstract

In order to determine the types of Candida spp. isolated from bloodstream cultures in Lyon, France, a retrospective study of isolates collected at five different bacteriology laboratories from 1998 to 2001 was conducted. During this period Candida spp. were isolated from 190 patients hospitalized in the internal medicine (32%), hematology (23%) and surgery (23%) wards, and in intensive care units (22%). C. albicans was the leading cause of Candida infection (49.5%), followed by C. glabrata (12.6%) and C. parapsilosis (12.1%). Among the onco-hematology patients, the major cause of candidemia was C. krusei (34%), followed by C. albicans (19%), while these two species were identified in 4% and 59% of patients in the other wards, respectively. In the single onco-hematology ward that was specialized in treating acute myeloid leukemia, 14 C. krusei isolates were identified in this study, which contrasts with the single C. krusei isolate recorded between 1992 and 1996. Since C. krusei has inherent resistance to the antifungal agent fluconazole, prophylactic use of fluconazole in these patients was investigated, but no relationship between these two parameters was found.

Ascioglu S, Rex JH, De Pauw B et al Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: an international consensus. Clin Infect Dis 34:7–14

Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel R (1998) National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 30:121–129

Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685–702

Sobel JD, Rex JH (2003) Invasive candidiasis: turning risk into a practical prevention policy. Clin Infect Dis 33:187–190

Pappas PG, Rex JH, Lee JL, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, NIAID Mycoses Study Group (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37:634–643

Hobson RP (2003) The global epidemiology of invasive Candida infections—is the tide turning? J Hosp Infect 55:159–168

Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ (2000) Bloodstream infections due to Candida species: sentry antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother 44:747–751

Slavin MA, Australian Mycology Interest Group (2002) The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 49(Suppl 1):3–6

Tortorano AM, Peman J, Berhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R, ECMM Working Group on Candidaemia (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317–322

10.

Richet H, Roux P, Des Champs C, Esnault Y, Andremont A, The French Candidemia Study Group (2002) Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 8:405–412

11.

Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA (2002) Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40:1298–1302

12.

Grillot R, Participants at the ECMM Candidemia Working Group (2000) ECMM prospective epidemiological survey of candidemia in Europe: report from France (682 cases). Rev Iberoam Micol 17(Suppl):144

13.

Godoy P, Tiraboshi IN, Severo LC, Bustamane B, Calvo B, De Almeida LP, Da Matta DA, Colombo AL (2003) Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz 98:401–405

14.

Pokoinen E, Lyytikäinen O, Anttila VJ, Ruutu P (2003) Candidemia in Finland, 1995–1999. Emerg Infect Dis 9:985–990

15.

Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW (2004) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42:1519–1527

16.

Al-Hedaithy SS (2003) The yeast species causing fungemia at a university hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses 46:293–298

17.

Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F (1999) Candidemia in cancer patients: a prospective multicenter surveillance study by the Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer. Clin Infect Dis 28:1071–1079

18.

Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, Han XY, Rolston KV, Safdar A, Raad II, Kontoyiannis DP (2003) Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 82:309–312

19.

Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122–1128

20.

Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, Kontoyiannis DP, Raad II (2002) The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 112:380–385

21.

Nakajima R, Kitamura A, Someya K, Tanaka M, Sato K (1995) In vitro and in vivo antifungal activites of DU-6858a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother 39:1517–1521

22.

Vitale RG, Afeltra J, De Hoog GS, Rijs AJ, Verweij PE (2003) In vitro activity of amphotericin B and itraconazole in combination with fluorocytosine, sulfadiazine and quinolones against Exophiala spinifera. J Antimicrob Chemother 51:1297–1300

23.

Sugar AM, Liu XP, Chen RJ (1997) Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother 41:2518–2521

Title: Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001
Authors: D. Martin
F. Persat
M.-A. Piens
S. Picot
Publication date: 01-05-2005
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-005-1321-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2005

A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole

Disseminated histoplasmosis in an HIV-infected patient discovered by routine blood smear staining

Clostridium clostridioforme: a mixture of three clinically important species

Isolation of Mycoplasma hominis from extragenital cultures

Comparison of genotypes of methicillin-resistant and methicillin-sensitive Staphylococcus aureus in Finland

Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials